FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure
Phase 3 data showed a 67% reduction in symptomatic infection among exposed household contacts who tested negative at baseline.
-
By
-
Kathryn Wighton
-
June 2, 2026
-
Clinical Scorecard: FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | SARS-CoV-2 main protease inhibitor that suppresses viral replication |
| Target Population | |
| Care Setting | |
Key Highlights
- First and only oral option for COVID-19 postexposure prophylaxis
- 67% reduction in symptomatic COVID-19 risk through day 10 compared to placebo
Guideline-Based Recommendations
Diagnosis
- Participants must test negative for SARS-CoV-2 at enrollment
Management
- Administer ensitrelvir as a 5-day regimen: three tablets on day 1, one tablet daily on days 2-5
Monitoring & Follow-up
- Monitor for adverse events, particularly headache, diarrhea, and cough
Risks
- No cases of dysgeusia attributed to ensitrelvir reported in the trial
Patient & Prescribing Data
Individuals aged 12 years and older exposed to symptomatic COVID-19
Effective in reducing symptomatic COVID-19 risk when administered postexposure
Clinical Best Practices
Related Resources & Content
